Hemerion team has been developing its technology since 2010 within the frame of scientific and clinical research teams located in Lille. Our endeavours led to a successful clinical validation in 2021.
The U.S. FDA authorizes Hemerion’s IND application for its Pentalafen® / Heliance® product combination
Read the press release
Hemerion raises €3.55 million to accelerate the implementation of international clinical trials for the treatment of glioblastoma
One year after the first round of funding, Hemerion’s new €3.55 million financing will accelerate the implementation of international clinical trials for the treatment of glioblastoma.
Mission in Boston: Hemerion prepares its development in the United States
Hemerion has set new milestones for its international development during a 5-day mission in Boston.
Hemerion awarded the Galien MedStartup Prize
Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA.
Phase II study granted authorization in Europe
Authorization granted for a phase 2 clinical trial that aims to evaluate the technology developed by Hemerion. This study is sponsored by the Lille University Hopital (France).
Preliminary results published in Journal of Neuro-Oncology
Ground breaking preliminary results from the clinical study are published in the Journal of Neuro-Oncology. The Hemerion’s technology covered the 2018’s May issue.
FDA grants Hemerion Orphan Drug designation
In the USA, the Hemerion’s technology becomes granted Orphan Drug Designation by the FDA.
Hemerion gathers 1.5M€ in funding
Hemerion wins the Réseau Entreprendre® award
Hemerion is one of the 2020 laureates of the Réseau Entreprendre®, the first international private network of business leaders, with 126 locations worldwide, grouped in 65 associations.
Hemerion wins Hodéfi award
Hemerion is one of the winners designated by Hodéfi, an association that finances and supports innovative companies in the Hauts-de-France region, and has received one of its first grants.
Therapeutic Innovation Prize
Hemerion wins the therapeutic innovation prize awarded by HDFID, an economic development and innovation agency supported by the Hauts de France Region.
Technology transfer
SATT Nord, a specialist in technology transfer from public research laboratories, grants Hemerion Therapeutics an exclusive license to exploit the anti-cancer technology co-developed by INSERM, the University of Lille and the Lille University Hospital.
Hemerion joins Neighborhood
Establishment of Hemerion Therapeutics
Hemerion Therapeutics is founded by the scientists and inventors of the technology, among them M. Vermandel, C. Dupont, N. Reyns, S. Mordon and M. Andraud gather deep scientific how-know and entrepreneurship skills to lead the company. In the mean time, Hemerion is awarded the French Tech Label that recognizes high potential start-up companies.
I-Lab innovation competition
University of Lille Foundation awards Hemerion Therapeutics
The University of Lille’s Foundation awards the Hemerion Therapeutics founders for their scientific and entrepreuneurship involvement establishing a healthtech company.
Introduction of the Hemerion technology in the USA
The Hemerion technology is demonstrated by Pr. N. Reyns at an international neurosurgery meeting in Cambridge – Boston (MA, USA) and in New-York (NY, USA) during Fluorescence-Guided Surgery Brain Tumor Symposiums hosted at The Icahn School of Medicine at Mount Sinai by Pr. C. G. Hadjipanayis.
European Neurosurgery Congress
The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.
Hemerion technology introduced in Nature
The clinical world premiere is highlighted in Nature’s 2018 September issue. An article detailing the clinical trial INDYGO and the technology being developed to treat glioblastomas is published in a special issue of journal (https://www.nature.com/articles/d41586-018-06713-6)
Patients enrollment successfully completed
The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.
Entrepreneurship program with Eurasanté
The Hemerion’s founders enter the Eurasanté entrepreneurship program, an incubator dedicated to health start-up companies
Awarded by world’s largest medical laser society
M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.
Kick-off of phase I clinical trial: INDYGO
Optimizing laser light delivery
The photonic therapy is further improved with a light power regimen study that leads to better tolerance.
New preclinical study confirms therapy effects
A new study allows to optimize the photonic illumination scheme and enhance the therapy effects.
Proof of concept
A first preclinical study proves the effectiveness of Hemerion therapeutics approach on glioblastoma (GBM) human cell lines. The experiments associated a photoactivatable drug and an innovative photonic system.